-
公开(公告)号:US07973078B2
公开(公告)日:2011-07-05
申请号:US12297445
申请日:2007-08-09
申请人: Hideki Kubota , Susumu Toda , Issei Tsukamoto , Yuta Fukuda , Ryutaro Wakayama , Kazuki Ono , Toru Watanabe , Hidenori Azami
发明人: Hideki Kubota , Susumu Toda , Issei Tsukamoto , Yuta Fukuda , Ryutaro Wakayama , Kazuki Ono , Toru Watanabe , Hidenori Azami
IPC分类号: C07C303/00 , A01N41/06
CPC分类号: C07C311/29 , A61K31/18 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/235 , A61K31/24 , A61K31/275 , A61K31/341 , A61K31/343 , A61K31/381 , A61K31/40 , A61K31/4015 , A61K31/404 , A61K31/415 , A61K31/4196 , A61K31/423 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , C07C311/14 , C07C311/19 , C07C311/21 , C07C311/47 , C07C311/51 , C07C323/49 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07D207/27 , C07D207/325 , C07D209/08 , C07D213/40 , C07D213/68 , C07D213/70 , C07D213/79 , C07D213/89 , C07D215/12 , C07D217/06 , C07D231/12 , C07D237/08 , C07D239/26 , C07D241/12 , C07D249/08 , C07D263/32 , C07D263/58 , C07D277/20 , C07D277/28 , C07D277/36 , C07D295/12 , C07D307/52 , C07D307/81 , C07D333/20 , C07D333/34 , C07D333/38 , C07D333/40 , C07D333/58
摘要: A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular a lower urinary tract symptom. It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.
摘要翻译: 可用作治疗与EP1受体相关疾病,特别是下尿路症状的药物的化合物。 证实具有酰胺结构的磺酰胺化合物,其特征在于其中酰胺中的碳原子与磺酰胺中的N原子通过低级亚烷基或其盐键合的化学结构具有有效的EP1受体拮抗活性,完成 本发明。 由于本发明的磺酰胺化合物或其药学上可接受的盐具有有效的EP1受体拮抗活性,因此可用作治疗与EP1受体,特别是下尿路症状相关的疾病的药剂。
-
公开(公告)号:US20090312328A1
公开(公告)日:2009-12-17
申请号:US12297445
申请日:2007-08-09
申请人: Hideki Kubota , Susumu Toda , Issei Tsukamoto , Yuta Fukuda , Ryutaro Wakayama , Kazuki Ono , Toru Watanabe , Hidenori Azami
发明人: Hideki Kubota , Susumu Toda , Issei Tsukamoto , Yuta Fukuda , Ryutaro Wakayama , Kazuki Ono , Toru Watanabe , Hidenori Azami
IPC分类号: A61K31/18 , C07C311/21 , C07D213/56 , C07D239/26 , C07D295/155 , C07D241/08 , A61K31/222 , A61K31/195 , A61K31/44 , A61K31/4406 , A61K31/505 , A61K31/4965 , A61K31/5375 , A61P13/00
CPC分类号: C07C311/29 , A61K31/18 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/235 , A61K31/24 , A61K31/275 , A61K31/341 , A61K31/343 , A61K31/381 , A61K31/40 , A61K31/4015 , A61K31/404 , A61K31/415 , A61K31/4196 , A61K31/423 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , C07C311/14 , C07C311/19 , C07C311/21 , C07C311/47 , C07C311/51 , C07C323/49 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07D207/27 , C07D207/325 , C07D209/08 , C07D213/40 , C07D213/68 , C07D213/70 , C07D213/79 , C07D213/89 , C07D215/12 , C07D217/06 , C07D231/12 , C07D237/08 , C07D239/26 , C07D241/12 , C07D249/08 , C07D263/32 , C07D263/58 , C07D277/20 , C07D277/28 , C07D277/36 , C07D295/12 , C07D307/52 , C07D307/81 , C07D333/20 , C07D333/34 , C07D333/38 , C07D333/40 , C07D333/58
摘要: [Object] A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.[Means for Solution] It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.
摘要翻译: [对象]可用作治疗与EP1受体,特别是下尿路症状相关的疾病的药剂的化合物。 [溶液的方法]确认具有酰胺结构的磺酰胺化合物,其特征在于其中酰胺中的氨基与磺酰胺中的N原子通过低级亚烷基或其盐键合的化学结构具有有效的EP1 受体拮抗活性,完成本发明。 由于本发明的磺酰胺化合物或其药学上可接受的盐具有有效的EP1受体拮抗活性,因此可用作治疗与EP1受体,特别是下尿路症状相关的疾病的药剂。
-
公开(公告)号:US08314240B2
公开(公告)日:2012-11-20
申请号:US13000677
申请日:2009-06-22
申请人: Hideki Kubota , Issei Tsukamoto , Kazunori Kamijo , Koji Kato , Yuta Fukuda , Hidenori Azami
发明人: Hideki Kubota , Issei Tsukamoto , Kazunori Kamijo , Koji Kato , Yuta Fukuda , Hidenori Azami
IPC分类号: A61K31/44 , C07D213/62
CPC分类号: C07C311/21 , A61K31/341 , A61K31/426 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/443 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , C07C2602/08 , C07D213/71 , C07D213/80 , C07D277/20 , C07D277/36 , C07D277/56 , C07D307/64 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12
摘要: [Object] A compound which is useful as an EP1 receptor antagonist is provided.[Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.
摘要翻译: 提供了可用作EP1受体拮抗剂的化合物。 [解决方案]本发明人研究了EP1受体拮抗剂,并证实了具有磺酰胺结构的化合物,其中磺酰胺结构的氮原子被2-氟丙基取代,3-氟-2-甲基丙基或 具有有效的EP1受体拮抗作用,从而完成本发明。 本发明的磺酰胺化合物具有有效的EP1受体拮抗作用,可用作预防和/或治疗下尿路症状等的药剂。
-
公开(公告)号:US20110201616A1
公开(公告)日:2011-08-18
申请号:US13000677
申请日:2009-06-22
申请人: Hideki Kubota , Issei Tsukamoto , Kazunori Kamijo , Koji Kato , Yuta Fukuda , Hidenori Azami
发明人: Hideki Kubota , Issei Tsukamoto , Kazunori Kamijo , Koji Kato , Yuta Fukuda , Hidenori Azami
IPC分类号: A61K31/501 , C07D213/71 , A61K31/4402 , C07D277/36 , A61K31/426 , C07D403/12 , A61K31/506 , C07D417/12 , A61K31/427 , C07D401/12 , A61K31/4439 , A61K31/444 , C07D307/64 , A61K31/341 , A61K31/497 , A61P13/00
CPC分类号: C07C311/21 , A61K31/341 , A61K31/426 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/443 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , C07C2602/08 , C07D213/71 , C07D213/80 , C07D277/20 , C07D277/36 , C07D277/56 , C07D307/64 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12
摘要: [Object] A compound which is useful as an EP1 receptor antagonist is provided.[Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.
摘要翻译: 提供了可用作EP1受体拮抗剂的化合物。 [解决方案]本发明人研究了EP1受体拮抗剂,并证实了具有磺酰胺结构的化合物,其中磺酰胺结构的氮原子被2-氟丙基取代,3-氟-2-甲基丙基或 具有有效的EP1受体拮抗作用,从而完成本发明。 本发明的磺酰胺化合物具有有效的EP1受体拮抗作用,可用作预防和/或治疗下尿路症状等的药剂。
-
公开(公告)号:US08669246B2
公开(公告)日:2014-03-11
申请号:US13498159
申请日:2010-09-24
申请人: Eiji Kawaminami , Tatsuhisa Takahashi , Takatoshi Kanayama , Yuta Fukuda , Hiroyuki Kaizawa , Yutaka Kondoh , Ryushi Seo , Kazuyuki Kuramoto , Kazuhiko Take , Kazuyuki Sakamoto
发明人: Eiji Kawaminami , Tatsuhisa Takahashi , Takatoshi Kanayama , Yuta Fukuda , Hiroyuki Kaizawa , Yutaka Kondoh , Ryushi Seo , Kazuyuki Kuramoto , Kazuhiko Take , Kazuyuki Sakamoto
IPC分类号: A61K31/341 , A61K31/381 , A61K31/401 , A61K31/415 , C07D207/34 , C07D213/81 , C07D263/34 , C07D277/56 , C07D307/68 , C07D333/38 , C07D417/12
CPC分类号: A61K31/426 , A61K31/341 , A61K31/381 , A61K31/401 , A61K31/415 , A61K31/42 , A61K31/427 , A61K31/44 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/4965 , C07D207/34 , C07D213/81 , C07D263/34 , C07D277/56 , C07D307/68 , C07D333/38 , C07D417/12
摘要: A substituted amide compound is useful as an active ingredient of a pharmaceutical composition, in particular a pharmaceutical composition for treating diseases caused by lysophosphatidic acid (LPA). The compound is of a formula: In this formula, A is an optionally substituted aryl, etc.; B is an optionally substituted 5-membered aromatic hetero ring group; X is a single bond or —(CRX1RX2)n—; n is 1, 2, 3, or 4; RX1 and RX2 are hydrogen, etc.; Y1 to Y5 are each CRY or N; each RY is hydrogen, etc.; R1 and R2 are hydrogen, etc.; m is 1, 2, or 3; R3 is hydrogen, etc.; and R4 is an optionally substituted lower alkyl, etc.
摘要翻译: 取代的酰胺化合物可用作药物组合物的活性成分,特别是用于治疗由溶血磷脂酸(LPA)引起的疾病的药物组合物。 该化合物具有下式:在该式中,A是任选取代的芳基等; B是任选取代的5元芳族杂环基团; X是单键或 - (CRX1RX2)n-; n为1,2,3或4; RX1和RX2是氢等; Y1〜Y5分别为CRY或N; 每个RY是氢等; R1和R2是氢等; m为1,2或3; R3是氢等; 并且R 4是任选取代的低级烷基等。
-
公开(公告)号:US20120184521A1
公开(公告)日:2012-07-19
申请号:US13498159
申请日:2010-09-24
申请人: Eiji Kawaminami , Tatsuhisa Takahashi , Takatoshi Kanayama , Yuta Fukuda , Hiroyuki Kaizawa , Yutaka Kondoh , Ryushi Seo , Kazuyuki Kuramoto , Kazuhiko Take , Kazuyuki Sakamoto
发明人: Eiji Kawaminami , Tatsuhisa Takahashi , Takatoshi Kanayama , Yuta Fukuda , Hiroyuki Kaizawa , Yutaka Kondoh , Ryushi Seo , Kazuyuki Kuramoto , Kazuhiko Take , Kazuyuki Sakamoto
IPC分类号: A61K31/426 , C07D417/12 , A61K31/427 , A61K31/496 , A61P43/00 , A61K31/513 , A61K31/538 , A61K31/454 , A61K31/541 , C07D277/56 , A61K31/4439
CPC分类号: A61K31/426 , A61K31/341 , A61K31/381 , A61K31/401 , A61K31/415 , A61K31/42 , A61K31/427 , A61K31/44 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/4965 , C07D207/34 , C07D213/81 , C07D263/34 , C07D277/56 , C07D307/68 , C07D333/38 , C07D417/12
摘要: A substituted amide compound is useful as an active ingredient of a pharmaceutical composition, in particular a pharmaceutical composition for treating diseases caused by lysophosphatidic acid (LPA). The compound is of a formula: In this formula, A is an optionally substituted aryl, etc.; B is an optionally substituted 5-membered aromatic hetero ring group; X is a single bond or —(CRX1RX2)n—; n is 1, 2, 3, or 4; RX1 and RX2 are hydrogen, etc.; Y1 to Y5 are each CRY or N; each RY is hydrogen, etc.; R1 and R2 are hydrogen, etc.; m is 1, 2, or 3; R3 is hydrogen, etc.; and R4 is an optionally substituted lower alkyl, etc.
摘要翻译: 取代的酰胺化合物可用作药物组合物的活性成分,特别是用于治疗由溶血磷脂酸(LPA)引起的疾病的药物组合物。 该化合物具有下式:在该式中,A是任选取代的芳基等; B是任选取代的5元芳族杂环基团; X是单键或 - (CRX1RX2)n-; n为1,2,3或4; RX1和RX2是氢等; Y1〜Y5分别为CRY或N; 每个RY是氢等; R1和R2是氢等; m为1,2或3; R3是氢等; 并且R 4是任选取代的低级烷基等。
-
-
-
-
-